Présentation de l'entreprise

“The microbiome industry is emerging, especially the notion of developing therapeutics sourced from gut microbiota. As of today, there are three main approaches: Fecal microbiotherapy (via enteral or oral adminstration), microbiota modulators (agonists or antagonists) or molecules mimicking microbial components or products. We compete in the field of developing drugs based on the concept of fecal microbiotherapy using a unique pooled technology allowing very high diversity restoration. This approach has showed the highest efficacy in the therapeutic area of Clostridium difficile.” from maatpharma.com